| abstract |
The application is directed to pharmaceutical combinations, compositions and kits comprising at least one H+/K+ ATPase inhibitor and an antibiotic compound and methods of use thereof in the treatment, prevention and amelioration of Helicobacter pylori infections in an individual. In alternative embodiments, the H+/K+ ATPase inhibitor is a potassium competitive acid blocker (PCAB) and the antibiotic compound is selected from the groups comprising penicillins, rifamycins, macrolides, PCABs, nitroimidazoles, fluoroquinolones, TG44, nitrofurans, thiazolides, salicylic acids and derivatives such as bismuths, and tetracyclines. |